Search | OpenScholar

Search results

374 results found

NINDS NET-PD Investigators. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis 2017;7:117-127.

Publication: Journal Article

Hauser, RA, R Li, A Perez, X Ren, D Weintraub, J Elm, JL Goudreau, et al. 2017. “NINDS NET-PD Investigators. Longer Duration of MAO-B Inhibitor Exposure Is Associated With Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1. J Parkinsons Dis 2017;7:117-127.”. J Parkinsons Dis.

Design of a cluster-randomized minority recruitment trial: RECRUIT. Clin Trials 2017;14:286-298.

Publication: Journal Article

Tilley, BC, AG Mainous, DW Smith, MD McKee, RP Amorrortu, J Alvidrez, V Diaz, et al. 2017. “Design of a Cluster-Randomized Minority Recruitment Trial: RECRUIT. Clin Trials 2017;14:286-298.”. Clin Trials.

Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord 2017;32:1335-1336.

Publication: Journal Article

Goetz, CG, GT Stebbins, KA Chung, AP Nicholas, RA Hauser, D Merkitch, and MA Stacy. 2017. “Topiramate As an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study. Mov Disord 2017;32:1335-1336.”. Mov Disord.

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 2017;89:1959-1969.

Publication: Journal Article

Mollenhauer, B, CJ Caspell-Garcia, CS Coffey, P Taylor, LM Shaw, JQ Trojanowski, A Singleton, et al. 2017. “Longitudinal CSF Biomarkers in Patients With Early Parkinson Disease and Healthy Controls. Neurology 2017;89:1959-1969.”. Neurology.

Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord 2016;33:127-133.

Publication: Journal Article

Wills, AA, JJ Elm, R Ye, KL Chou, SA Parashos, RA Hauser, I Bodis-Wollner, et al. 2016. “Cognitive Function in 1736 Participants in NINDS Exploratory Trials in PD Long-Term Study-1. Parkinsonism Relat Disord 2016;33:127-133.”. Parkinsonism Relat Disord.

Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Int J Neurosci 2016;126:20-24

Publication: Journal Article

Kumar, R, RA Hauser, J Mostillo, N Dronamraju, A Graf, M Merschemke, and C Kenney. 2016. “Mavoglurant (AFQ056) in Combination With Increased Levodopa Dosages in Parkinson’s Disease Patients. Int J Neurosci 2016;126:20-24”. Int J Neurosci.

Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015;72:88-95.

Publication: Journal Article

Smith, KM, E Eyal, D Weintraub, and Adagio Investigators. 2015. “Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study: Effects on Nonmotor Symptoms and Tolerability. JAMA Neurol 2015;72:88-95.”. JAMA Neurol.

Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. Evid Based Med 2015;20:17.

Publication: Journal Article

Hauser, RA. 2015. “Initial Choice of Medication Has Little Effect on Short-Term or Long-Term Outcome for Most Patients With Parkinson’s Disease. Evid Based Med 2015;20:17.”. Evid Based Med.

Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. Mov Disord 2015;30:589-92.

Publication: Journal Article

Poewe, W, RA Hauser, and A Lang. 2015. “Effects of Rasagiline on the Progression of Nonmotor Scores of the MDS-UPDRS. Mov Disord 2015;30:589-92.”. Mov Disord.

Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis 2015;5:773-82.

Publication: Journal Article

Bega, D, S Kim, Y Zhang, J Elm, J Schneider, R Hauser, A Fraser, and T Simuni. 2015. “Predictors of Functional Decline in Early Parkinson’s Disease: NET-PD LS1 Cohort. J Parkinsons Dis 2015;5:773-82.”. J Parkinsons Dis.